Yong-Hong Xu Selected Research

Nanodiamonds

9/2021	Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
10/2020	Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes.
10/2019	Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
1/2019	Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.
1/2019	Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates.
10/2018	Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
7/2014	Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yong-Hong Xu Research Topics

Disease

7	Neoplasms (Cancer) 12/2022 - 07/2014
5	Glioblastoma (Glioblastoma Multiforme) 10/2020 - 12/2017
1	Neoplasm Metastasis (Metastasis) 03/2022
1	Oral Ulcer (Mouth Ulcer) 03/2022
1	Breast Neoplasms (Breast Cancer) 03/2022
1	Esophageal Stenosis (Esophageal Stricture) 03/2022
1	Lung Neoplasms (Lung Cancer) 09/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Triple Negative Breast Neoplasms 10/2019
1	Brain Neoplasms (Brain Tumor) 10/2018
1	Liver Neoplasms (Liver Cancer) 01/2015
1	Hepatitis B 01/2015
1	Hepatocellular Carcinoma (Hepatoma) 01/2015
1	Stomach Neoplasms (Stomach Cancer) 06/2009

Drug/Important Bio-Agent (IBA)

7	NanodiamondsIBA 09/2021 - 07/2014
7	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2021 - 10/2018
6	polyglycerolIBA 01/2021 - 07/2014
3	Pharmaceutical PreparationsIBA 12/2022 - 07/2014
1	HMGB1 Protein (HMG1)IBA 09/2021
1	CytokinesIBA 09/2021
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2021
1	phytochlorinIBA 01/2021
1	Photosensitizing Agents (Photosensitizers)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2019
1	Cytostatic AgentsIBA 10/2019
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2015
1	NF-kappa B (NF-kB)IBA 01/2015
1	beta 2-Glycoprotein I (Apolipoprotein H)IBA 01/2015
1	LipopolysaccharidesIBA 01/2015
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2015
1	Drug CarriersIBA 07/2014
1	arginyl-glycyl-aspartic acidIBA 07/2014
1	Peptides (Polypeptides)IBA 07/2014
1	alisol BIBA 06/2009
1	Acetates (Acetic Acid Esters)FDA Link 06/2009

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 03/2022 - 07/2014
2	Therapeutics 10/2020 - 12/2017
1	Modified Radical Mastectomy (Mastectomy, Modified) 03/2022
1	Ligation 09/2021
1	Photochemotherapy (Photodynamic Therapy) 01/2021
1	Immunotherapy 10/2019
1	Combined Modality Therapy 10/2018